Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06106334 · ClinicalTrials.gov registry record · Phase 1

Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants

A Phase 1 study of Obesity and Healthy Volunteers, sponsored by Shionogi.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target
1
Study location

NCT06106334: Completed Phase 1 study of Obesity and Healthy Volunteers, sponsored by Shionogi.

NCT06106334 is a Phase 1 study of Obesity and Healthy Volunteers that has completed, run by Shionogi. The registered enrollment target is 14 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06106334, a Phase 1 study of Obesity and Healthy Volunteers, has completed, sponsored by Shionogi.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

The primary purpose of this study is to determine the effect of repeated administration of itraconazole on the pharmacokinetic (PK) profile of S-309309; and the PK of S-309309 following administration of S-309309 alone and co-administration with itraconazole

Interventions

  • DRUG Itraconazole
  • DRUG S309309

Study Locations (1)

Texas

  • Fortrea Clinical Research Unit Inc. - Dallas

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2023-11-15
Est. Completion 2024-02-14
Phase Phase 1
Shionogi

54 total trials

What the finished NCT06106334 record still lists

NCT06106334 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Itraconazole is the first listed.

NCT06106334 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06106334 about?

NCT06106334 is a clinical study titled "Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants". The primary purpose of this study is to determine the effect of repeated administration of itraconazole on the pharmacokinetic (PK) profile of S-309309; and the PK of S-309309 following administration of S-309309 alone and co-administration with itraconazole

What is the current status of trial NCT06106334?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2023-11-15. Estimated completion is 2024-02-14.

What conditions does trial NCT06106334 study?

This clinical trial studies the following conditions: Obesity, Healthy Volunteers.

What interventions are being tested in trial NCT06106334?

The interventions under investigation include: Itraconazole (DRUG), S309309 (DRUG).

Who is sponsoring clinical trial NCT06106334?

This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06106334 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06106334's enrollment target sits among peer trials

14 1009th of 1053 higher than 44 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT06106334, the US trial registry maintained by the National Library of Medicine. NCT06106334 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.